Table 1.
Baseline clinicopathological characteristics of IgAN patients in different therapies.
| Characteristics | Groups | p-value | ||
|---|---|---|---|---|
| SC (n = 146) | CS (n = 325) | IT (n = 244) | ||
| Follow-up (months) | 44.69 ± 24.13 | |||
| Clinical | ||||
| Male gender (%) | 69 (47.3) | 151 (46.5) | 116 (47.5) | 0.996 |
| Age (years) | 34.29 ± 10.24 | 32.15 ± 11.36 | 33.52 ± 11.33 | 0.113 |
| Hypertension (%)ab | 41 (28.1) | 95 (29.2) | 95 (38.9) | 0.023 |
| Nephrotic syndrome (%)ac | 2 (1.4) | 90 (27.7) | 53 (21.7) | <0.001 |
| SBP (mmHg)b | 129.51 ± 18.56 | 126.37 ± 18.56 | 133 ± 20.18 | <0.001 |
| DBP (mmHg) | 83.19 ± 14.06 | 81.86 ± 13.10 | 84.68 ± 14.83 | 0.058 |
| Serum creatinine (μmol/L)ab | 86.37 ± 27.55 | 83.28 ± 26.64 | 95.23 ± 28.82 | <0.001 |
| eGFR (ml/min per 1.73 m2)b | 93.86 ± 26.99 | 100.95 ± 71.77 | 85.04 ± 28.44 | 0.002 |
| Urine protein (g/24 h)ac | 1.74 ± 0.876 | 3.61 ± 3.15 | 3.71 ± 2.62 | <0.001 |
| Serum albumin (g/L)ac | 40.49 ± 4.08 | 35.06 ± 8.79 | 36.42 ± 7.00 | <0.001 |
| Uric acid (μmol/L) | 368.42 ± 96.91 | 359.21 ± 101.64 | 374.95 ± 94.85 | 0.163 |
| CKD stage | <0.001 | |||
| Stage 1 (%) | 81 (55.5) | 196 (60.3) | 100 (41.0) | |
| Stage 2 (%) | 48 (32.9) | 92 (28.3) | 91 (37.3) | |
| Stage 3a (%) | 17 (11.6) | 37 (11.4) | 53 (21.7) | |
| Pathologic (Oxford classification) | ||||
| M1 (%)ab | 108 (74.0) | 244 (75.1) | 211 (86.5) | 0.001 |
| E1 (%)ac | 1 (0.7) | 17 (5.2) | 23 (9.4) | 0.001 |
| S1 (%)ab | 74 (50.7) | 154 (47.4) | 156 (63.9) | <0.001 |
| T1/T2 (%)ab | 23 (15.8) | 45 (13.8) | 63 (25.8) | 0.001 |
| C1/C2 (%)abc | 17 (11.6) | 77 (23.7) | 86 (35.2) | <0.001 |
Data presented as number (percentage) or mean ± SD. eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; M, mesangial proliferation; E, endocapillary proliferation; S, segmental sclerosis; T, tubular atrophy/interstitial fibrosis; C, crescents; SC, supportive care group; CS, corticosteroids; IT, immunosuppressive therapy.
a
Stands for p < 0.05 between SC and IT.
b
Stands for p < 0.05 between CS and IT.
c
Stands for p < 0.05 between SC and CS.